Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 4Neoplasms 2Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Oligodendroglioma 1Metastatic Castration-resistant Prostate Cancer 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Lymphadenopathy 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × cabazitaxel × Clear all
NCT02202772 2025-02-24

CGC

Columbia University

Phase 1/2 Active not recruiting
51 enrolled

Carcinoma, Neoplasms, Recurrence

NCT01001221 2013-09-11

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Sanofi

Phase 1/2 Terminated
19 enrolled 55 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡